Treatment effects of Eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial)

American Journal of Cardiology

Volumn 91, Issue 1, 2003, Pages 17-21

  Reddan, Donal N ^a,b,c,d,e,f   O'Shea, John Conor ^a,b,c,d,e   Sarembock, Ian J ^a,b,c,d,e   Williams, Kathryn A ^a,b,c,d,e   Pieper, Karen S ^a,b,c,d,e   Santoian, Edward ^a,b,c,d,e   Owen Jr , William F ^a,b,c,d,e   Kitt, Michael M ^a,b,c,d,e   Tcheng, James E ^a,b,c,d,e  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c Cardiovascular Research Center   (United States)

^d Orlando Heart Center   (United States)

^e MILLENNIUM PHARMACEUTICALS INC   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO; TICLOPIDINE; WARFARIN;

ADULT; AGE; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; KIDNEY FUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHI-SQUARE DISTRIBUTION; CORONARY DISEASE; CREATININE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION INHIBITORS; STENTS; TREATMENT OUTCOME;

EID: 0037218936     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02991-0     Document Type: Article

References (26)

1. Jones C.A., McQuillan G.M., Kusek J.W., Eberhardt M.S., Herman W.H., Coresh J., Salive M., Jones C.P., Agodoa L.Y. Serum creatinine levels in the US population Third National Health and Nutrition Examination Survey . Am J Kidney Dis. 32:1998;992-999.
2. Mann J.F., Gerstein H.C., Pogue J., Bosch J., Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril the HOPE randomized trial . Ann Intern Med. 134:2001;629-636.
3. Fried L.P., Kronmal R.A., Newman A.B., Bild D.E., Mittelmark M.B., Polak J.F., Robbins J.A., Gardin J.M. Risk factors for 5-year mortality in older adults the Cardiovascular Health Study . JAMA. 279:1998;585-592.
4. McCullough P.A., Soman S.S., Shah S.S., Smith S.T., Marks K.R., Yee J., Borzak S. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol. 36:2000;679-684.
5. Muntner P., He J., Hamm L., Loria C., Whelton P.K. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 13:2002;745-753.
6. Anderson R.J., O'Brien M., MaWhinney S., VillaNueva C.B., Moritz T.E., Sethi G.K., Henderson W.G., Hammermeister K.E., Grover F.L., Shroyer A.L. Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery. VA Cooperative Study #5. Kidney Int. 55:1999;1057-1062.
7. Herzog C.A., Ma J.Z., Collins A.J. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 339:1998;799-805.
8. Herzog C.A., Ma J.Z., Collins A.J. Long-term outcome of dialysis patients in the United States with coronary revascularization procedures. Kidney Int. 56:1999;324-332.
9. Rubenstein M.H., Harrell L.C., Sheynberg B.V., Schunkert H., Bazari H., Palacios I.F. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation. 102:2000;2966-2972.
10. O'Shea J.C., Hafley G.E., Greenberg S., Hasselblad V., Lorenz T.J., Kitt M.M., Strony J., Tcheng J.E. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention a randomized controlled trial . JAMA. 285:2001;2468-2473.
11. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet 2000;356:2037-2044.
12. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41.
13. O'Shea J.C., Madan M., Cantor W.J., Pacchiana C.M., Greenberg S., Joseph D.M., Kitt M.M., Lorenz T.J., Tcheng J.E. Design and methodology of the ESPRIT trial evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention . Am Heart J. 140:2000;834-839.
14. Rao A.K., Pratt C., Berke A., Jaffe A., Ockene I., Schreiber T.L., Bell W.R., Knatterud G., Robertson T.L., Terrin M.L. Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I. Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 11:1988;1-11.
15. Landefeld C.S., Cook E.F., Flatley M., Weisberg M., Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. 82:1987;703-713.
16. Kidney Disease Outcome Initiative Group. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002;39(suppl 2):S1-246.
17. Assmann S.F., Pocock S.J., Enos L.E., Kasten L.E. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 355:2000;1064-1069.
18. Yusuf S., Wittes J., Probstfield J., Tyroler H.A. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 266:1991;93-98.
19. Rockette H.E., Caplan R.J. Strategies for subgroup analysis in clinical trials. Recent Results Cancer Res. 111:1988;49-54.
20. Gradaus F., Schoebel F.C., Ivens K., Jax T.W., Heering P., Strauer B.E., Leschke M. Rate of restenosis after PTCA in patients with terminal renal failure. A quantitative coronary angiography study. Z Kardiol. 86:1997;373-379.
21. Schoebel F.C., Gradaus F., Ivens K., Heering P., Jax T.W., Grabensee B., Strauer B.E., Leschke M. Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease a case-control study using quantitative coronary angiography . Heart. 78:1997;337-342.
22. Reddan D.N. Therapy for cardiovascular disease in patients with chronic kidney disease appropriate caution or the absence of data . Am Heart J. 144:2002;206-207.
23. Alton K.B., Kosoglou T., Baker S., Affrime M.B., Cayen M.N., Patrick J.E. Disposition of 14C-eptifibatide after intravenous administration to healthy men. Clin Ther. 20:1998;307-323.
24. Boneu B., Caranobe C., Sie P. Pharmacokinetics of heparin and low molecular weight heparin. Baillieres Clin Haematol. 3:1990;531-544.
25. Zachee P., Vermylen J., Boogaerts M.A. Hematologic aspects of end-stage renal failure. Ann Hematol. 69:1994;33-40.
26. Peto R. Misleading subgroup analyses in GISSI. Am J Cardiol. 66:1990;771-772.